Drugs / AAV9.hMCOLN1co
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07398872 | Jan 2026 → Jan 2027 expected | mucolipidosis type IV | The Children's Hospital of Zhejiang University School of Medicine | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV9.hMCOLN1co | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07398872 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV9. hMCOLN1co, a gene therapy product” NCT07398872 ↗ |
| Route | Intrathecal | “A single intrathecal infusion” NCT07398872 ↗ |